Base de dados : MEDLINE
Pesquisa : C01.703.492 [Categoria DeCS]
Referências encontradas : 129 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 129 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29218389
[Au] Autor:Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
[Ad] Endereço:Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. sibylle.mellinghoff@uk-koeln.de.
[Ti] Título:Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
[So] Source:Ann Hematol;97(2):197-207, 2018 Feb.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Hospedeiro Imunocomprometido
Infecções Fúngicas Invasivas/prevenção & controle
Leucemia Mieloide Aguda/terapia
Síndromes Mielodisplásicas/terapia
Prevenção Primária/métodos
[Mh] Termos MeSH secundário: Ensaios Clínicos como Assunto
Monitoramento de Medicamentos
Hematologia
Transplante de Células-Tronco Hematopoéticas
Seres Humanos
Quimioterapia de Indução
Infecções Fúngicas Invasivas/imunologia
Infecções Fúngicas Invasivas/microbiologia
Leucemia Mieloide Aguda/imunologia
Leucemia Mieloide Aguda/patologia
Oncologia
Síndromes Mielodisplásicas/imunologia
Síndromes Mielodisplásicas/patologia
Sociedades Médicas
Triazóis/uso terapêutico
Voriconazol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Triazoles); 6TK1G07BHZ (posaconazole); JFU09I87TR (Voriconazole)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3196-2


  2 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28911042
[Au] Autor:McCarthy MW; Kontoyiannis DP; Cornely OA; Perfect JR; Walsh TJ
[Ad] Endereço:Division of General Internal Medicine, Weill Cornell Medicine, New York, New York.
[Ti] Título:Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.
[So] Source:J Infect Dis;216(suppl_3):S474-S483, 2017 Aug 15.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The emergence of drug-resistant fungi poses a major threat to human health. Despite advances in preventive, diagnostic, and therapeutic interventions, resistant fungal infections continue to cause significant morbidity and mortality in patients with compromised immunity, underscoring the urgent need for new antifungal agents. In this article, we review the challenges associated with identifying broad-spectrum antifungal drugs and highlight novel targets that could enhance the armamentarium of agents available to treat drug-resistant invasive fungal infections.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Farmacorresistência Fúngica Múltipla
Fungos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Fungos/genética
Seres Humanos
Infecções Fúngicas Invasivas/tratamento farmacológico
Transdução de Sinais
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170916
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix130


  3 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28841131
[Au] Autor:Goh LC; Shakri ED; Ong HY; Mustakim S; Shaariyah MM; Ng WSJ; Zulkiflee AB
[Ad] Endereço:Department of Otorhinolaryngology,University of Malaya,Kuala Lumpur,Malaysia.
[Ti] Título:A seven-year retrospective analysis of the clinicopathological and mycological manifestations of fungal rhinosinusitis in a single-centre tropical climate hospital.
[So] Source:J Laryngol Otol;131(9):813-816, 2017 Sep.
[Is] ISSN:1748-5460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the clinicopathological and mycological manifestations of fungal rhinosinusitis occurring in the Tengku Ampuan Rahimah Hospital, in Klang, Malaysia, which has a tropical climate. METHODS: Records of patients treated from 2009 to 2016 were analysed retrospectively. Data from the records were indexed based on age, gender, clinical presentations, symptom duration, clinical signs and mycological growth. RESULTS: Of 80 samples, 27 (33.75 per cent) had fungal growth. Sixteen patients were classified as having non-invasive fungal rhinosinusitis and 11 as having invasive fungal rhinosinusitis. The commonest clinical presentation was nasal polyposis in non-invasive fungal rhinosinusitis patients (p < 0.05) and ocular symptoms in invasive fungal rhinosinusitis patients (p < 0.05). The commonest organism was aspergillus sp. (p < 0.05) in non-invasive fungal rhinosinusitis and mucorales in invasive fungal rhinosinusitis. CONCLUSION: There is an almost equal distribution of both invasive and non-invasive fungal rhinosinusitis, as seen in some Asian countries. Invasive fungal rhinosinusitis, while slightly uncommon when compared to non-invasive fungal rhinosinusitis, is potentially life threatening, and may require early and extensive surgical debridement. The clinical presentation of nasal polyposis was often associated with non-invasive fungal rhinosinusitis, whereas ocular symptoms were more likely to be associated with invasive fungal rhinosinusitis.
[Mh] Termos MeSH primário: Infecções Fúngicas Invasivas/epidemiologia
Micoses/epidemiologia
Rinite/microbiologia
Sinusite/microbiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Malásia/epidemiologia
Masculino
Meia-Idade
Micoses/classificação
Estudos Retrospectivos
Centros de Atenção Terciária
Clima Tropical
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170826
[St] Status:MEDLINE
[do] DOI:10.1017/S0022215117001505


  4 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28792943
[Au] Autor:Talbot JJ; Houbraken J; Frisvad JC; Samson RA; Kidd SE; Pitt J; Lindsay S; Beatty JA; Barrs VR
[Ad] Endereço:Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Camperdown, New South Wales, Australia.
[Ti] Título:Discovery of Aspergillus frankstonensis sp. nov. during environmental sampling for animal and human fungal pathogens.
[So] Source:PLoS One;12(8):e0181660, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Invasive fungal infections (IFI) due to species in Aspergillus section Fumigati (ASF), including the Aspergillus viridinutans species complex (AVSC), are increasingly reported in humans and cats. The risk of exposure to these medically important fungi in Australia is unknown. Air and soil was sampled from the domiciles of pet cats diagnosed with these IFI and from a nature reserve in Frankston, Victoria, where Aspergillus viridinutans sensu stricto was discovered in 1954. Of 104 ASF species isolated, 61% were A. fumigatus sensu stricto, 9% were AVSC (A. felis-clade and A. frankstonensis sp. nov.) and 30% were other species (30%). Seven pathogenic ASF species known to cause disease in humans and animals (A. felis-clade, A. fischeri, A. thermomutatus, A. lentulus, A. laciniosus A. fumisynnematus, A. hiratsukae) comprised 25% of isolates overall. AVSC species were only isolated from Frankston soil where they were abundant, suggesting a particular ecological niche. Phylogenetic, morphological and metabolomic analyses of these isolates identified a new species, A. frankstonensis that is phylogenetically distinct from other AVSC species, heterothallic and produces a unique array of extrolites, including the UV spectrum characterized compounds DOLD, RAIMO and CALBO. Shared morphological and physiological characteristics with other AVSC species include slow sporulation, optimal growth at 37°C, no growth at 50°C, and viriditoxin production. Overall, the risk of environmental exposure to pathogenic species in ASF in Australia appears to be high, but there was no evidence of direct environmental exposure to AVSC species in areas where humans and cats cohabitate.
[Mh] Termos MeSH primário: Aspergilose/epidemiologia
Aspergillus/classificação
Aspergillus/isolamento & purificação
Monitoramento Ambiental/métodos
Infecções Fúngicas Invasivas/epidemiologia
[Mh] Termos MeSH secundário: Animais
Antifúngicos/farmacologia
Aspergilose/microbiologia
Aspergillus/efeitos dos fármacos
Aspergillus/genética
Austrália/epidemiologia
Sequência de Bases
Gatos
DNA Fúngico/genética
Exposição Ambiental
Seres Humanos
Infecções Fúngicas Invasivas/microbiologia
Testes de Sensibilidade Microbiana
Naftóis/metabolismo
Filogenia
Análise de Sequência de DNA
Microbiologia do Solo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (DNA, Fungal); 0 (Naphthols); 35483-50-2 (viriditoxin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170810
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181660


  5 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28774702
[Au] Autor:Colombo AL; de Almeida Júnior JN; Slavin MA; Chen SC; Sorrell TC
[Ad] Endereço:Department of Medicine, Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: arnaldolcolombo@gmail.com.
[Ti] Título:Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer.
[So] Source:Lancet Infect Dis;17(11):e344-e356, 2017 Nov.
[Is] ISSN:1474-4457
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Critically ill patients and patients with haematological cancer are HIV-negative populations at high risk of invasive fungal infections. In intensive-care units, candidaemia and intra-abdominal candidiasis predominate, but aspergillosis has emerged as a lethal, under-recognised cause of pneumonia. In patients with haematological malignancies or who have undergone stem-cell transplantations, pulmonary disease due to aspergillus and other mould diseases predominate. In this Series paper, we provide an update on risk assessment, new diagnostic strategies, and therapeutic approaches. New concepts have emerged for use of risk prediction rules and an evidence base now exists for inclusion of biomarkers (eg, galactomannan, 1,3-ß-D-glucan, and PCR assays for Aspergillus spp) into early diagnostic and therapeutic strategies. Imaging techniques remain helpful for early diagnosis of pulmonary mould diseases, with PET techniques offering potential improvements in diagnostic specificity and evaluation of clinical response. Echinocandins and triazoles have been validated extensively for prophylaxis, empirical therapy, and targeted therapy, but an increase in intrinsically resistant fungi and emergence of secondary resistance as a result of drug-induced selection pressure are of major concern. Echinocandins remain a major component of treatment of invasive candidiasis and new triazoles are the best alternative for prophylaxis and therapy of invasive aspergillosis.
[Mh] Termos MeSH primário: Candida/isolamento & purificação
Estado Terminal
Fungos/isolamento & purificação
Neoplasias Hematológicas/complicações
Infecções Fúngicas Invasivas/epidemiologia
Infecções Fúngicas Invasivas/microbiologia
[Mh] Termos MeSH secundário: Antifúngicos/uso terapêutico
Biomarcadores/análise
Técnicas de Apoio para a Decisão
Testes Diagnósticos de Rotina/métodos
Equinocandinas/uso terapêutico
Seres Humanos
Infecções Fúngicas Invasivas/diagnóstico
Infecções Fúngicas Invasivas/tratamento farmacológico
Tomografia por Emissão de Pósitrons
Medição de Risco
Triazóis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Biomarkers); 0 (Echinocandins); 0 (Triazoles)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170805
[St] Status:MEDLINE


  6 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28592049
[Au] Autor:Chinese Invasive Fungal Infection Working Group
[Ti] Título:[The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the fifth revision)].
[So] Source:Zhonghua Nei Ke Za Zhi;56(6):453-459, 2017 Jun 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Invasive fungal disease(IFD) is a common yet highly lethal complication in patients with hematological malignancies receiving chemotherapy or stem cell transplantation, as well as immune suppressive conditions including aplastic anemia and other malignancies. According to the diagnostic criteria, patients are defined as proven, probable, possible and undefined IFD based on the evidence provided by histopathologic/cytologic, culture, radiographic and biomarker examinations. For the management of IFD, the major treatment strategies consist of prophylaxis, empirical, diagnostic-driven and target therapy. The Chinese Invasive Fungal Infection Working Group has developed the Chinese consensus for the diagnosis and treatment of invasive fungal disease based on international guidelines and local experience. Recently, the working group revises the consensus by update international guidelines and clinical studies in China.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Doenças Hematológicas/complicações
Neoplasias Hematológicas/complicações
Infecções Fúngicas Invasivas/diagnóstico
Infecções Fúngicas Invasivas/tratamento farmacológico
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Adulto
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
China
Consenso
Feminino
Fungos
Seres Humanos
Masculino
Transplante de Células-Tronco/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2017.06.015


  7 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566663
[Au] Autor:Hirai K; Inukai T; Nakayama H
[Ad] Endereço:Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science.
[Ti] Título:Promising Therapies for Fungal Infection Based on the Study to Elucidate Mechanisms to Cope with Stress in Candida Species [Translated Article].
[So] Source:Med Mycol J;58(2):E79-E86, 2017.
[Is] ISSN:1882-0476
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:In recent years, the incidence of fungal infections has been increasing, particularly among patients with immune systems compromised by human immunodeficiency virus infection, organ transplantation, and/or chemotherapy for cancer. Current therapies for treating systemic fungal infection have limited effectiveness and have created problems of adverse reactions and drug resistance. These issues therefore motivate us to develop novel antifungals. Elucidation of stress response mechanisms and virulence factors in pathogenic fungi is required in developing an effective antifungal strategy. There are actually numerous studies concerning various stress responses in several important fungal pathogens. Among these responses, we focused on stress response for iron starvation to identify potential targets for novel antifungals because iron starvation occurs in blood, where pathogenic fungi often infect. Here we show recent progress of studies on iron homeostasis in Candida species, especially focusing on Candida glabrata, and propose novel antifungal targets.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Candida glabrata/metabolismo
Candida glabrata/patogenicidade
Candidíase/tratamento farmacológico
Candidíase/microbiologia
Descoberta de Drogas
Infecções Fúngicas Invasivas/tratamento farmacológico
Infecções Fúngicas Invasivas/microbiologia
Micoses/tratamento farmacológico
[Mh] Termos MeSH secundário: Antifúngicos/efeitos adversos
Homeostase
Seres Humanos
Hospedeiro Imunocomprometido
Ferro/metabolismo
Fatores de Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Virulence Factors); E1UOL152H7 (Iron)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.3314/mmj.17.007


  8 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28496146
[Au] Autor:Perfect JR
[Ad] Endereço:Duke University Medical Center, 200 Trent Drive, Durham, North Carolina 27710, USA.
[Ti] Título:The antifungal pipeline: a reality check.
[So] Source:Nat Rev Drug Discov;16(9):603-616, 2017 Sep.
[Is] ISSN:1474-1784
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Invasive fungal infections continue to appear in record numbers as the immunocompromised population of the world increases, owing partially to the increased number of individuals who are infected with HIV and partially to the successful treatment of serious underlying diseases. The effectiveness of current antifungal therapies - polyenes, flucytosine, azoles and echinocandins (as monotherapies or in combinations for prophylaxis, or as empiric, pre-emptive or specific therapies) - in the management of these infections has plateaued. Although these drugs are clinically useful, they have several limitations, such as off-target toxicity, and drug-resistant fungi are now emerging. New antifungals are therefore needed. In this Review, I discuss the robust and dynamic antifungal pipeline, including results from preclinical academic efforts through to pharmaceutical industry products, and describe the targets, strategies, compounds and potential outcomes.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Antifúngicos/uso terapêutico
Descoberta de Drogas
Avaliação Pré-Clínica de Medicamentos
Infecções Fúngicas Invasivas/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Farmacorresistência Fúngica/efeitos dos fármacos
Seres Humanos
Modelos Biológicos
Terapia de Alvo Molecular/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE
[do] DOI:10.1038/nrd.2017.46


  9 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28422065
[Au] Autor:Levesque E; Rizk F; Noorah Z; Aït-Ammar N; Cordonnier-Jourdin C; El Anbassi S; Bonnal C; Azoulay D; Merle JC; Botterel F
[Ad] Endereço:Department of Anaesthesia and Surgical Intensive Care-Liver ICU, AP-HP Henri Mondor Hospital, 51 Avenue du Marechal de Lattre de Tassigny, 94100 Créteil, France. eric.levesque@aphp.fr.
[Ti] Título:Detection of (1,3)-ß-d-Glucan for the Diagnosis of Invasive Fungal Infection in Liver Transplant Recipients.
[So] Source:Int J Mol Sci;18(4), 2017 Apr 19.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Invasive fungal infections (IFI) are complications after liver transplantation involving high morbidity and mortality. (1,3)-ß-d-glucan (BG) is a biomarker for IFI, but its utility remains uncertain. This study was designed to evaluate the impact of BG following their diagnosis. Between January 2013 and May 2016, 271 liver transplants were performed in our institution. Serum samples were tested for BG (Fungitell , Associates Cape Code Inc., Falmouth, MA, USA) at least weekly between liver transplantation and the discharge of patients. Nineteen patients (7%) were diagnosed with IFI, including 13 cases of invasive candidiasis (IC), eight cases of invasive pulmonary aspergillosis, and one case of septic arthritis due to . Using a single BG sample for the primary analysis of IFI, 95% (21/22) of the subjects had positive BG (>80 pg/mL) at the time of IFI diagnosis. The area under the ROC curves to predict IFI was 0.78 (95% CI: 0.73-0.83). The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of BG for IFI were 75% (95% CI: 65-83), 65% (62-68), 17% (13-21), and 96% (94-97), respectively. Based on their high NPV, the BG test appears to constitute a good biomarker to rule out a diagnosis of IFI.
[Mh] Termos MeSH primário: Infecções Fúngicas Invasivas/sangue
Infecções Fúngicas Invasivas/etiologia
Transplante de Fígado/efeitos adversos
beta-Glucanas/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Antifúngicos/uso terapêutico
Biomarcadores
Quimioprevenção
Feminino
Seres Humanos
Infecções Fúngicas Invasivas/diagnóstico
Infecções Fúngicas Invasivas/prevenção & controle
Masculino
Meia-Idade
Mortalidade
Curva ROC
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Biomarkers); 0 (beta-1,3-D-glucan); 0 (beta-Glucans)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE


  10 / 129 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28397466
[Au] Autor:Zhu P; Lv J; Kong Y; Xu H; Ming L
[Ti] Título:Absolute Eosinophil Count was Significantly Associated with Serum (1,3)-ß-D-Glucan in Patients with Invasive Fungal Infections.
[So] Source:Clin Lab;63(4):749-756, 2017 Apr 01.
[Is] ISSN:1433-6510
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Measurement of serum (1,3)-ß-D-glucan has emerged as an important diagnostic strategy for invasive fungal infections (IFI). Previous studies suggested that the eosinophil count would be related with the value of serum (1,3)-ß-D-glucan. METHODS: 572 blood samples obtained from 126 patients at the First Affiliated Hospital of Zhengzhou University were analyzed. The unsuitable samples were excluded according to the patient selection. RESULTS: In our study, we found that in the 572 cumulative results, the absolute eosinophil count was significantly associated with the value of (1,3)-ß-D-glucan (r = 0.57; 95% confidence interval (CI) 0.51 - 0.63) but not with total leukocyte, neutrophils, lymphocytes, monocytes, and basophils. Then, we found that there were 126 patients with invasive fungal infections, 109 patients with candidiasis and 17 patients with aspergillosis. In the 109 patients who had candidiasis, absolute eosinophil count was significantly associated with the value of (1,3)-ß-D-glucan (r = 0.59; 95% CI 0.53 - 0.65). Similarly, in the 17 patients who had aspergillosis, the absolute eosinophil count was significantly associated with the value of (1,3)-ß-D-glucan (r = 0.65; 95% CI 0.51 - 0.75). Meanwhile, similar findings in different types of Candida species or Aspergillus species in patients were found except in Candida glabrata infection. CONCLUSIONS: As a routine and broadly used test, serial absolute eosinophil count is related with IFI, and it could be used to evaluate the progress of IFI.
[Mh] Termos MeSH primário: Eosinófilos
[Mh] Termos MeSH secundário: Aspergilose
Glucanos
Seres Humanos
Infecções Fúngicas Invasivas
Micoses
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucans)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.7754/Clin.Lab.2016.161017



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde